Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "TD"

1160 News Found

Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr
News | November 10, 2024

Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr

Hospital business revenues increase 13.9% to Rs. 1,655 crore


JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
News | November 07, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth


Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
News | November 07, 2024

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter


RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
News | November 07, 2024

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25


Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
News | November 06, 2024

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.


Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
News | November 06, 2024

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24


Imtiyaz Basade appointed Senior VP of NATCO Pharma
People | November 05, 2024

Imtiyaz Basade appointed Senior VP of NATCO Pharma

He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.


Biocon reports Q2 FY25 net loss at Rs. 16 Cr
News | November 04, 2024

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore


USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
Drug Approval | November 02, 2024

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature